UNSPSC 51284113: Cefsulodin

This classification denotes an anti-bacterial agent with the molecular formula C22H20N4O8S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OV42LHE42B, chemically known as 4-carbamoyl-1-(((6r,7r)-2-carboxy-8-oxo-7-((2r)-2-phenyl-2-sulfoacetamido)-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)pyridinium hydroxide, inner salt, monosodium salt but generally known as cefsulodin, which bears US NIH Compound Identifier 40246.

UNSPSC 51284113 Cefsulodin, a Commodity-level code, appears in recent state and local procurement primarily for pharmaceutical products and medical supplies rather than cefsulodin specifically. The opportunities being solicited under this code frame the work as procurement of generic pharmaceuticals, over-the-counter products, naloxone, drug deactivation systems, and medical first aid supplies for distribution through state health agencies, county health departments, and municipal fire departments. Issuing bodies include state health and human services commissions, county health departments, municipal fire departments, and cooperative purchasing alliances spanning multiple states. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, and the Texas Health and Human Services Commission appear as state-level buyers, while Seminole County, Florida and the City of Tampa represent county and municipal health and emergency response procurement.

Recent activity spans Florida, Texas, Minnesota, and Oregon. Representative opportunities include Seminole County's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries; the City of Tampa's IFB 26P00145 (due March 13, 2026) for 169 line items of medical and first aid supplies for the Tampa Fire Department Rescue Division with an estimated contract value of $700,000.00 and a sheltered-market set-aside for certified Small Local Business Enterprises; and MMCAP's RFP S1070000015802 (due March 26, 2026) for multiple contracts covering generic pharmaceuticals and OTC products to be distributed across participating state and local facilities. The Texas HHS Commission issued an RFI (HHS0017013, posted April 3, 2026) to explore direct-to-manufacturer prescription programs. Most recent opportunities show no explicit set-aside restrictions except Tampa's SLBE designation; E-Verify compliance and drug-free workplace certification appear as standard compliance requirements.